50,000 Shares in Maze Therapeutics, Inc. $MAZE Purchased by Seven Grand Managers LLC

Seven Grand Managers LLC acquired a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $2,072,000.

Other hedge funds have also modified their holdings of the company. Washington University grew its holdings in shares of Maze Therapeutics by 33.3% during the fourth quarter. Washington University now owns 280,802 shares of the company’s stock worth $11,634,000 after buying an additional 70,121 shares in the last quarter. Mass General Brigham Inc bought a new position in shares of Maze Therapeutics during the fourth quarter worth about $9,943,000. ArrowMark Colorado Holdings LLC bought a new position in shares of Maze Therapeutics during the third quarter worth about $14,135,000. Boothbay Fund Management LLC grew its holdings in shares of Maze Therapeutics by 365.9% during the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after buying an additional 276,345 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after buying an additional 362,060 shares in the last quarter.

Wall Street Analyst Weigh In

MAZE has been the subject of a number of research reports. Truist Financial decreased their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. HC Wainwright increased their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Wedbush increased their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Finally, BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $66.00.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 25,582 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total value of $665,643.64. Following the completion of the sale, the chief executive officer directly owned 350,987 shares in the company, valued at $9,132,681.74. The trade was a 6.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the sale, the insider owned 10,503 shares of the company’s stock, valued at $266,461.11. This trade represents a 41.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 119,502 shares of company stock valued at $4,246,639. Company insiders own 5.30% of the company’s stock.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE opened at $26.05 on Thursday. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 12 month low of $9.73 and a 12 month high of $53.65. The stock has a 50 day moving average of $29.69 and a 200-day moving average of $37.61. The company has a market capitalization of $1.44 billion, a P/E ratio of -10.30 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. As a group, equities research analysts predict that Maze Therapeutics, Inc. will post -2.74 EPS for the current year.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.